OMER Omeros Corporation

19.62
+1.04  (+6%)
Previous Close 18.58
Open 18.64
Price To Book -7.43
Market Cap 967,022,653
Shares 49,287,597
Volume 710,813
Short Ratio
Av. Daily Volume 453,091

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

First module of rolling BLA submission due by mid-4Q 2019.
OMS721
Hematopoietic stem cell-associated TMA (HSCT-TMA)
Phase 3 trial enrollment initiated February 2018. Continues to enrol as of August 2019.
OMS721
IgA nephropathy
Phase 2 data released October 2016.
OMS721
Kidney disorders
Approved June 2, 2014.
Omidria
Cataract surgery
Phase 3 enrollment has opened - noted March 16, 2017.
OMS721
Atypical hemolytic uremic syndrome (aHUS)
Phase 1 data available "soon" - noted August 8, 2019. Estimate 2H 2019.
OMS527
Nicotine Addiction

Latest News

  1. Edited Transcript of OMER earnings conference call or presentation 8-Aug-19 8:30pm GMT
  2. Omeros to Present at the 2019 Wedbush PacGrow Healthcare Conference
  3. Omeros (OMER) Q2 2019 Earnings Call Transcript
  4. Omeros (OMER) Reports Q2 Loss, Tops Revenue Estimates
  5. Omeros Corporation Reports Second Quarter 2019 Financial Results
  6. Omeros Corporation to Announce Second Quarter 2019 Financial Results on August 8, 2019
  7. Will Omeros (OMER) Report Negative Q2 Earnings? What You Should Know
  8. Omeros and Lonza Enter Long-Term Manufacturing Agreement for Commercial Supply of Narsoplimab
  9. The Omeros (NASDAQ:OMER) Share Price Has Gained 31% And Shareholders Are Hoping For More
  10. Omeros’ OMIDRIA® Receives Product-Specific J-Code from CMS
  11. Calls Pop as Drug Stock Gets FDA Boost
  12. Omeros, FDA Agree On Endpoint For Pivotal Trial Of Small Blood Vessel Damage Treatment
  13. Omeros Announces Agreement with FDA on Primary Endpoint for Narsoplimab BLA in Stem Cell Transplant-Associated TMA
  14. Edited Transcript of OMER earnings conference call or presentation 9-May-19 8:30pm GMT
  15. Omeros Corporation Announces Assignment of Rapporteurs for European Marketing Authorization Application for Narsoplimab for Treatment of HSCT-TMA
  16. Is Omeros Corporation's (NASDAQ:OMER) CEO Paid At A Competitive Rate?
  17. Omeros to Present at the UBS Global Healthcare Conference
  18. Omeros (OMER) Reports Q1 Loss, Lags Revenue Estimates
  19. Omeros: 1Q Earnings Snapshot